Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.68 |
| ▸ | NAALAD2 | Q9Y3Q0 | 7/20 | 0.68 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22037239 | 1.00 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19209760 | 1.00 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12145778 | 1.00 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12654762 | 0.89 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14115633 | 0.89 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12291706 | 0.88 | FOLH1 (0.50) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL11936652 | 0.84 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22636039 | 0.84 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14331633 | 0.84 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL11936625 | 0.84 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252534-B2 | Humanized anti-CD3 antibodies, conjugates and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3411069-B1 | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-109069635-B | Humanized anti-CD 3 antibodies, conjugates and uses thereof | 斯克利普斯研究所 | 2023-09-26 | — | — | CN | disclosed |
| US-20230192844-A1 | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2023-06-22 | — | — | US | disclosed |
| EP-3411069-A2 | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF | The California Institute for Biomedical Research (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017136659-A2 | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-08-10 | — | — | WO | disclosed |
| US-9415113-B2 | Targeting monomers and polymers having targeting blocks | UNIVERSITY OF WASHINGTON (US) | 2016-08-16 | — | — | US | disclosed |
| US-20130011362-A1 | TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS | PHASERX, INC. (US) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011362-A1 | TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS | FOLR1, FOLR2, DHFR | FOLH1 14/4885NAALAD2 3927/4885RIMKLA 675/4885 |
| US-20230192844-A1 | HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF | CD2, CD47, KLK3 | FOLH1 43/4885NAALAD2 172/4885RIMKLA 2261/4885 |
| US-12252534-B2 | Humanized anti-CD3 antibodies, conjugates and uses thereof | CD2, CD47, KLK3 | FOLH1 43/4885NAALAD2 172/4885RIMKLA 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.